Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2

Brief Bioinform. 2021 Mar 22;22(2):714-725. doi: 10.1093/bib/bbaa416.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an unprecedented threat to public health. The pandemic has been sweeping the globe, impacting more than 200 countries, with more outbreaks still lurking on the horizon. At the time of the writing, no approved drugs or vaccines are available to treat COVID-19 patients, prompting an urgent need to decipher mechanisms underlying the pathogenesis and develop curative treatments. To fight COVID-19, researchers around the world have provided specific tools and molecular information for SARS-CoV-2. These pieces of information can be integrated to aid computational investigations and facilitate clinical research. This paper reviews current knowledge, the current status of drug development and various resources for key steps toward effective treatment of COVID-19, including the phylogenetic characteristics, genomic conservation and interaction data. The final goal of this paper is to provide information that may be utilized in bioinformatics approaches and aid target prioritization and drug repurposing. Several SARS-CoV-2-related tools/databases were reviewed, and a web-portal named OverCOVID (http://bis.zju.edu.cn/overcovid/) is constructed to provide a detailed interpretation of SARS-CoV-2 basics and share a collection of resources that may contribute to therapeutic advances. These information could improve researchers' understanding of SARS-CoV-2 and help to accelerate the development of new antiviral treatments.

Keywords: COVID-19; SARS-CoV-2; bioinformatics; coronavirus; drug development; regulatory interactions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Biomedical Research*
  • COVID-19 / virology*
  • COVID-19 Drug Treatment
  • Computational Biology*
  • Drug Repositioning
  • Humans
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / physiology*

Substances

  • Antiviral Agents